IFCC certifies EKF Diagnostics point-of-care analyser
Global diagnostics company EKF Diagnostics has announced that its Quo-Lab HbA1c point-of-care analyser has successfully achieved International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certification. The analyser offers laboratory-accurate results from just 4 µL of blood with a user-friendly interface.

Glycated haemoglobin (HbA1c) testing is globally recognised as the gold standard in monitoring of diabetic patients, enabling more complete control of their disease management. The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, accepted worldwide as the analytical control for traceability of HbA1c measurement.
To participate in the program, manufacturers are required to register and report the results of 24 samples (two per month) from across the measurement range. The samples are supplied by an IFCC reference laboratory.
“The awarding of this certification allows us to report results traceable to the IFCC reference method for quantitative determination of HbA1c,” said Gavin Jones, diabetes product manager, EKF Diagnostics. “Together with the existing NGSP certification we achieved from 2012, the IFCC award demonstrates conclusively that Quo-Lab meets all of the demanding standards set by independent certifying bodies.”
Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director
Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
Optics11 Life appoints Jacquelien ten Dam as CEO
Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...
